InvestorsHub Logo
Followers 83
Posts 36201
Boards Moderated 0
Alias Born 03/09/2010

Re: None

Wednesday, 02/04/2015 4:38:34 PM

Wednesday, February 04, 2015 4:38:34 PM

Post# of 403103
March 5, 2014 Press release

“As I have stated before, we have set in motion several initiatives that will have significant impact on Elite’s future,” commented Nasrat Hakim, Elite’s President and CEO. “Following the success of the pilot bioequivalence study in December for ELI-201, we are delighted with the results of this pivotal bioequivalence clinical study for ELI-200, our second opioid abuse deterrent product. ELI-200 is expected to be filed this year and will be the first NDA product filed by Elite with the U.S. Food and Drug Administration.”


hmmmmmmm, what price did the stock yet THAT day. LOL
Yeah I guess he was just suggesting.

THEY HATE ME CAUSE THEY AINT ME

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News